Oral Drugs Related with Muscle Wasting and Sarcopenia. A Review.

Pharmacology

Department of Pharmacy, Hospital de Mataró, Consorci Sanitari del Maresme, Mataró, Barcelona, Spain.

Published: March 2017

Sarcopenia is a geriatric syndrome characterized by progressive and generalized loss of skeletal muscle mass and function. Reported prevalence of this geriatric syndrome, differs depending on the definition, the population and the method used to identify sarcopenia. The causes of sarcopenia are multifactorial, and can include genetic influence, immobility or disuse, endocrine factors, inflammation and nutritional deficiencies. These disorders involve an imbalance between anabolic and catabolic pathways that rules muscle mass. Many drugs taken regularly for common conditions may interact with some mechanisms that can alter the balance between protein synthesis and degradation. This may lead to a harmful or a beneficial effect on muscle mass and strength. Widely prescribed drugs could play an important role during the time of onset and development of sarcopenia. In this paper, we reviewed the current understanding of how can drugs contribute positively or negatively on sarcopenia and muscle wasting. We decided to focus this review on oral common drugs, which are usually prescribed in older adults, leaving aside other drugs as hormone therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1159/000448247DOI Listing

Publication Analysis

Top Keywords

muscle mass
12
muscle wasting
8
geriatric syndrome
8
sarcopenia
6
muscle
5
drugs
5
oral drugs
4
drugs muscle
4
wasting sarcopenia
4
sarcopenia review
4

Similar Publications

WHY ARE WE NOT EXPLORING THE POTENTIAL OF LOWER LIMB MUSCLE POWER TO IDENTIFY PEOPLE WITH SARCOPENIA?

Ageing Res Rev

January 2025

Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy; Department of Geriatrics and Orthopedics, Università Cattolica del Sacro Cuore, Rome, Italy. Electronic address:

Sarcopenia refers to a neuromuscular disease characterized by age-related declines in muscle mass and function. Since Professor Rosenberg first introduced the concept of sarcopenia in 1989, numerous operational paradigms have been proposed, tested, and validated against negative outcomes. The most recent recommendations advocate that dynapenia, or reduced of muscle strength, should be used alongside low muscle mass for the identification of sarcopenia.

View Article and Find Full Text PDF

Possible sarcopenia, sarcopenic obesity phenotypes and their association with diabetes: Evidence from LASI wave-1 (2017-18).

Diabetes Metab Syndr

January 2025

Department of Anthropology, University of Delhi, Delhi, 110007, India; Laboratory of Kinanthropometry, Ergonomics and Physiological Anthropology, Department of Anthropology, University of Delhi, Delhi, 110007, India. Electronic address:

Aims: To assess the prevalence of possible sarcopenia and sarcopenic obesity phenotypes and investigate their association with self-reported diabetes among community-dwelling individuals aged 45 or above.

Methods: Utilizing data from 62,899 individuals in LASI wave-1 (2017-18), the assessment of possible sarcopenia was done on two critical parameters: muscle (handgrip) strength and physical performance (gait speed), following the 2019 guidelines from the Asian working group on sarcopenia (AWGS). BMI, WC, WHR, and WHtR defined sarcopenic obesity phenotypes.

View Article and Find Full Text PDF

Background: The association between skeletal muscle and adipose tissue (body composition) and early response using positron emission tomography (PET) in pediatric Hodgkin lymphoma (HL) remains unstudied.

Methods: Patients enrolled on Children's Oncology Group studies AHOD0031 (intermediate-risk HL) and AHOD0831 (high-risk HL) with digital abdominal computed tomography (CT) scans at diagnosis and PET scans after 2 cycles (PET2) were included. Two consecutive slices at the third lumbar vertebra were identified and skeletal muscle index (SMI, in cm2/m2) and total adipose tissue index (TATI, in cm2/m2) were calculated using sliceOmatic (Magog, Canada) and height at diagnosis.

View Article and Find Full Text PDF

Background: Meeting protein intake recommendations is relevant for maintaining muscle mass. This study aimed to describe protein intake and its association with meal patterns and dietary patterns.

Methods: An in-house designed, web-based 4-day record was used in the national dietary survey (in 2010/2011).

View Article and Find Full Text PDF

Background: Cancer-associated cachexia can inhibit immune checkpoint inhibitor (ICI) therapy efficacy. Cachexia's effect on ICI therapy has not been studied in large cohorts of cancer patients aside from lung cancer. We studied associations between real-world routinely collected clinical cachexia markers and disability-free, hospitalization-free and overall survival of cancer patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!